Finding protein biomarkers for AMD, diabetic retinopathy, and retinal detachment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-center, prospective translational interventional effort enrolling about 260 participants including patients with AMD, diabetic retinopathy, retinal detachment, and control surgical patients. Clinical sampling includes peripheral blood, tears, and—when collected during routine care—aqueous humor, vitreous humor, and subretinal fluid. Advanced clinical proteomics will be applied to these biological matrices to identify molecular signatures linked to disease onset, progression, and treatment response. The goal is to validate protein biomarkers that improve understanding of disease mechanisms and support new diagnostic or prognostic tools.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years
* Ability to understand the study procedures and provide written informed consent
* Willingness and ability to comply with study procedures and visits

For case subjects:

* Patients with age-related macular degeneration (intermediate or advanced, including geographic atrophy or neovascular AMD)
* Patients with diabetic retinopathy (non-proliferative or proliferative, with or without diabetic macular edema)
* Patients undergoing surgery for primary or recurrent retinal detachment

For control subjects:

* Patients scheduled for cataract surgery with no documented retinal diseases (e.g., AMD, diabetic retinopathy, retinal vascular occlusions, or retinal epithelial disorders)
* Outpatients with no documented retinal diseases
* For retinal detachment subgroup: patients undergoing macular surgery (e.g., macular pucker or macular hole) or cataract surgery with attached retina

Exclusion Criteria:

* Age \< 18 years
* Presence of infectious ocular diseases
* Alterations in the electrophoretic profile of gamma globulins

Where it's running

• IRCCS Fondazione G.B.Bietti
  Roma, Italy, Italy Recruiting

Study contacts

• Study coordinator: Mariacristina Parravano, MD
• Email: mariacristina.parravano@fondazionebietti.it
• Phone: +390684009442

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AI-assisted eye screening for diabetic retinopathy and age-related macular degeneration in outpatient clinics

  This project will test whether the VeriSee AI software helps doctors find diabetic eye disease and macular degeneration earlier in adults with diabetes or people aged 50 and older.

  Recruiting National Taiwan University Hospital · Taipei · NCT07069647

• VeriSee AI for screening macular degeneration and diabetic retinopathy

  This trial will test whether the VeriSee AI software can help doctors screen for age-related macular degeneration in adults 50+ and diabetic retinopathy in diabetic adults 20+.

  Recruiting National Taiwan University Hospital · Taipei, Taiwan · NCT06843499

• Automated AI system to detect diabetic retinopathy in adults with diabetes

  A AI-based software device is being tested to automatically detect diabetic retinopathy from retinal images in adults with diabetes.

  Recruiting Digital Diagnostics, Inc. · Jacksonville, Florida · NCT07844317

• Biometry in Eyes with Silicon Oil After PPV

  This study tests optical and ultrasound biometry in people with retinal detachment who are getting pars plana vitrectomy with silicone oil, to see how measurements compare before surgery and about a month after.

  Recruiting Sohag University · Sohag · NCT07731984

• N-acetylcysteine for diabetic retinopathy in adults with type 2 diabetes

  This study tests whether taking N-acetylcysteine for three months can help people with type 2 diabetes who have mild to moderate diabetic retinopathy.

  Recruiting at 2 sites Phase 4 Ain Shams University · Cairo and 1 other locations · NCT07634991

• Early imaging changes with faricimab versus biosimilar ranibizumab for diabetic retinal disease

  This trial will see if faricimab or a biosimilar ranibizumab causes different early OCT and OCTA imaging changes in adults with diabetic retinopathy or diabetic macular edema who need anti-VEGF injections.

  Recruiting Osijek University Hospital · Osijek · NCT07520045

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.